BioCryst Pharma Q3 operating profit up, raises FY ORLADEYO sales guidance

BioCryst Pharmaceuticals

03/11/2025 12:13

Overview

BioCryst Q3 operating profit increased 285% y-o-y, reflecting strong leverage

ORLADEYO Q3 revenue up 37% y-o-y, driven by strong patient demand

Company raises FY 2025 ORLADEYO revenue guidance

Outlook

BioCryst raises FY 2025 ORLADEYO revenue guidance to $590-$600 mln

Company lowers FY 2025 non-GAAP operating expenses to $430-$440 mln

Company expects positive cash flows and net income for FY 2025

Result Drivers

ORLADEYO SALES - Strong patient demand and new prescriber engagement drove 37% y-o-y increase in ORLADEYO revenue

EUROPEAN BUSINESS SALE - Sale of European ORLADEYO business improved financial leverage and enabled debt retirement

STRATEGIC ACQUISITION - Planned acquisition of Astria Therapeutics to expand HAE portfolio and drive growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Sales
$159.39 mln
Q3 EPS
$0.06
Q3 Net Income
$12.89 mln
Q3 Operating Expenses
$129.80 mln


Press Release: ID:nGNX7x555n

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)